Blood test may guide cancer care without biopsy

NCT ID NCT07673861

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovarian cancer. The test looks for genetic changes that may indicate resistance to current therapy or suggest alternative treatments. A panel of experts reviews the results to see if they can guide therapy choices, offer additional prognostic information, or eliminate the need for a tissue biopsy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Marsden360 ctDNA test

What this could lead to

If successful, this approach could make cancer care more personalized by using a simple blood test to guide treatment decisions and reduce the need for invasive biopsies.

What could go wrong

This is an early-stage study with only 100 participants, so results may not apply to all patients. The test may not always provide useful information or change treatment plans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms colorectal cancer colorectal neoplasm gastrointestinal stromal tumor non-small cell lung carcinoma ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Royal Marsden NHS Foundation Trust

    RECRUITING

    London, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••